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Aims Adipose tissue and inflammation may play a role in the pathophysiology of patients with heart failure (HF) with mildly
reduced or preserved ejection fraction. We therefore investigated epicardial fat in patients with HF with preserved
(HFpEF) and mid-range ejection fraction (HFmrEF), and related this to co-morbidities, plasma biomarkers and cardiac
structure.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
A total of 64 HF patients with left ventricular ejection fraction >40% and 20 controls underwent routine cardiac
magnetic resonance examination. Epicardial fat volume was quantified on short-axis cine stacks covering the entire
epicardium and was related to clinical correlates, biomarkers associated with inflammation and myocardial injury, and
cardiac function and contractility on cardiac magnetic resonance. HF patients and controls were of comparable age,
sex and body mass index. Total epicardial fat volume was significantly higher in HF patients compared to controls
(107mL/m2 vs. 77mL/m2, P <0.0001). HF patients with atrial fibrillation and/or type 2 diabetes mellitus had more
epicardial fat than HF patients without these co-morbidities (116 vs. 100mL/m2, P =0.03, and 120 vs. 97mL/m2,
P =0.001, respectively). Creatine kinase-MB, troponin T and glycated haemoglobin in patients with HF were positively
correlated with epicardial fat volume (R=0.37, P =0.006; R=0.35, P =0.01; and R=0.42, P =0.002, respectively).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion Heart failure patients had more epicardial fat compared to controls, despite similar body mass index. Epicardial fat
volume was associated with the presence of atrial fibrillation and type 2 diabetes mellitus and with biomarkers related
to myocardial injury. The clinical implications of these findings are unclear, but warrant further investigation.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Heart failure with preserved ejection fraction • Heart failure with mid-range ejection fraction •
Epicardial fat • Atrial fibrillation • Cardiac magnetic resonance imaging
Introduction
Heart failure (HF) with left ventricular ejection fraction (LVEF)
>40% is an increasingly large health problem with a morbidity
and mortality similar to HF with reduced ejection fraction (HFrEF,
LVEF <40%).1,2 Despite its increasing prevalence, no specific ther-
apies have been proven beneficial in terms of reducing morbidity
and mortality, which could be related to the heterogeneity of the
disease.3 HF with LVEF >40% is characterized by different phe-
notypes that might require specific treatments.4,5 Many of these
patients are obese and there is increasing evidence that adipose
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.. tissue and the associated inflammation may play a role in the patho-
physiology of HF and appears to be a distinct phenotype within the
HF spectrum.6,7
Epicardial fat has been shown to excrete several
pro-inflammatory chemokines and cytokines, collectively called
adipokines, in obese patients.8 Epicardial fat volume was shown to
be increased in several systemic diseases, such as the metabolic
syndrome and obesity, which are known to induce a systemic
pro-inflammatory state.9–11 Given these associations, it is con-
ceivable that epicardial fat is also involved in the pathophysiology
of HF.8 Due to the close anatomical relation between epicardial
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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fat and the myocardium, epicardial fat may have local inflammatory
and mechanical effects on the myocardium and the coronary
arteries. Via these adipokine-mediated inflammatory mechanisms,
‘epicardial’ obesity might cause adverse myocardial remodelling in
HF, particularly in those with LVEF >40%. The role of epicardial fat
has been studied in healthy subjects and in patients with diabetes
mellitus using cardiac magnetic resonance (CMR).12,13 Another
study has examined epicardial fat volume in patients with HFrEF,
and found that it was decreased compared to healthy controls.11
So far, however, no studies have been conducted in HF patients
with LVEF >40%.
In the present study, we therefore investigated the extent
and location of epicardial fat volume using CMR. We explored
the relation of epicardial fat with co-morbidities, with biomark-
ers and with myocardial function and contractility parameters
on CMR in patients with HF with LVEF >40% and compared
these findings to controls. Given the recent distinction between
patients with LVEF 40–50% (HF with mid-range ejection fraction,
HFmrEF) and patients with LVEF >50% (HF with preserved ejec-




We enrolled symptomatic HF patients (New York Heart Associa-
tion functional class ≥II) who had a LVEF >40% on echocardiogra-
phy. They also had an N-terminal pro-hormone of brain natriuretic
peptide (NT-proBNP) level> 125 ng/L and echocardiographic evi-
dence of left ventricular diastolic dysfunction, left atrial dilata-
tion and/or left ventricular hypertrophy, according to the current
European Society of Cardiology criteria.3 All patients underwent
standard CMR imaging, and they were excluded for the present
analysis if they had LVEF ≤40% on CMR, (corrected) congenital
heart disease, or if they had more than moderate left-sided valvular
disease. All patients were part of a standard work-up/protocol for
HF patients with an LVEF >40%. This protocol consisted of a thor-
ough examination including laboratory testing, echocardiography
and CMR if echocardiography was inconclusive about the cause of
HFpEF. A total of 49 of the 64 HF patients with LVEF >40% partici-
pated in the Ventricular Tachyarrhythmia Detection by Implantable
Loop Recording in Patients with Heart Failure and Preserved
Ejection Fraction (VIP-HF) registry (NCT01989299). This registry
was designed to evaluate the incidence of sustained ventricular
arrhythmias in patients with HFpEF, monitored by implantable loop
recorder. The VIP-HF study was approved by the ethics committee
of our hospital, and all patients gave written informed consent. The
remaining 15 patients were collected from the screening database.
Controls were age-, sex- and body mass index (BMI)-matched and
underwent CMR mostly because they had a first-degree relative
with a cardiomyopathy, so there was an indication for family screen-
ing, but the patients were all free of signs and symptoms of HF.
Controls were included if CMR showed no signs of structural
heart defects. We excluded those with a documented history of



















































































.. artery disease. The inclusion of controls and non-VIP-HF HF
patients was approved by the local ethics committee. This study
was in concordance with the principles outlined in the Declaration
of Helsinki.
Cardiac magnetic resonance imaging
Cardiac magnetic resonance imaging was performed using a stan-
dard protocol for the acquisition of cardiac volumes and func-
tional parameters, as previously published by our group.14 In
short, all CMR studies were performed using a 1.5 Tesla scan-
ner (Siemens, Erlangen, Germany). ECG-triggered cine loop images
were obtained during breath hold at end-expiration, using a ret-
rospectively gated cine steady-state free-precession sequence.
Approximately 15 short-axis slices from base to apex were
obtained, including both atria.
Cardiac magnetic resonance images were analysed off-line by
two observers (G.v.W. and T.M.G.) using dedicated software
(QMass 7.6, QStrain 2.0, Medis, Leiden, The Netherlands). Endo-
cardial and epicardial borders of the left and right ventricle were
manually delineated on the end-diastolic and end-systolic phases
on the short-axis stacks. End-diastolic and end-systolic volumes
were automatically calculated by the summation of slices multi-
plied by slice thickness method. Volumetric measurements were
indexed for body surface area (BSA). Using the long-axis slices, left
atrial and right atrial volumes were measured by tracing the area
and length of both atria in end-systole and end-diastole. Atrial vol-
ume was approximated using the area–length method.15 To assess
ventricular contractility, tissue tracking analysis was performed on
cine imaging. Strain was measured as the total deformation of the
myocardium from its baseline length to its maximum length, and is
expressed as a percentage.16 Left ventricular circumferential strain
was measured on the short axis at base, mid-ventricular and api-
cal level, left ventricular longitudinal strain was measured on the
four-chamber and two-chamber cine images, and right ventricular
longitudinal strain was measured on the four-chamber view.
Epicardial fat is the adipose tissue situated between the
outer wall of the myocardium and the visceral layer of the
pericardium.17,18 Epicardial fat was manually delineated on
end-diastolic short-axis slices, working from the most basal
slice towards the most apical slice (Figure 1).18,19 The mitral valve
annulus position was used to differentiate between atrial and
ventricular epicardial fat. Epicardial fat volumes were calculated
by summation of epicardial fat volume of each slice using the
modified Simpson’s rule.20 All epicardial fat measurements were
done by one investigator (G.v.W.) after training. All epicardial fat
measurements were reviewed by a second fully blinded observer
(T.P.W.) who randomly checked the measurements by repeating
them. No variability of >10% was found between the observers. In
addition, the presence of epicardial fat was verified by measuring
pre- and post-contrast T1 times of the myocardium, epicardial
fat, subcutaneous fat, and the blood pool using T1 mapping at
mid-ventricular level. This way, it was ensured that epicardial fat
volume included primarily adipose tissue and not fluids, since T1
times of epicardial fat and subcutaneous fat were comparable.
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Upper figure shows a short-axis series, moving from basal to apical slices. The myocardium is shown in red, the visceral layer of the
pericardium in green, the parietal layer of the pericardium in yellow, the pericardial fat border in blue.
Echocardiography
Echocardiographic parameters were assessed according to the
current recommendations for cardiac chamber quantification and
included: left ventricular and right ventricular systolic function,
left ventricular diastolic function (E, A, E/A ratio, e’, and E/e’
ratio), valvular stenosis and/or regurgitation, and the peak pressure
gradient across the tricuspid valve.21 In addition, the absence
of pericardial effusion to ensure the reliability of epicardial fat
measurements was also verified on echocardiography.
Biomarkers
Plasma biomarkers for HF (NT-proBNP), inflammation [C-reactive
protein (CRP) and leucocytes], myocardial damage [troponin T,
creatine kinase muscle–brain fraction (CK-MB)], type 2 diabetes
mellitus [glycated haemoglobin (HbA1c)] and renal function [esti-
mated glomerular filtration rate (eGFR)] were obtained from med-
ical records within 3months before or after CMR imaging. Plasma
biomarkers were not available for controls.
Statistical analysis
Data are presented as numbers (percentage), mean±standard devi-
ation or median with interquartile ranges, depending on distri-
bution. Differences in continuous variables between groups were
analysed using the independent samples t-test or Wilcoxon rank
test, depending on distribution. Differences in categorical vari-
ables between groups were analysed using the Chi-squared test
or Fisher’s exact test. Correlations between clinical, CMR and
biomarker parameters with the amount and location of epicar-
dial fat were analysed using Pearson’s or Spearman’s correlation,
depending on distribution. Associations between epicardial fat,
clinical parameters and HF were analysed using a multivariable



















































.. transformed prior to the analysis. Statistical analyses were per-
formed using SPSS (version 23, SPSS Inc., Chicago, IL, USA). Statis-
tical significance was considered at a P-value <0.05.
Results
Patient characteristics
We examined 70 HF patients with LVEF >40% and 20 controls.
In six HF patients (8.5%), the atria were not included in the
short-axis measurements, and therefore total epicardial fat could
not be calculated and these patients were excluded. The final
study population thus consisted of 64 HF patients and 20 con-
trols. Patient characteristics of the study population are depicted
in Table 1. There were no significant differences regarding age,
sex, and BMI between HF patients and controls. Characteristics
of HFpEF and HFmrEF patients are depicted in the online supple-
mentary Table S1. NT-proBNP was higher in HFmrEF compared
to HFpEF.
Epicardial fat and cardiac function
in heart failure versus controls
Despite similar BMI, total and ventricular epicardial fat volume
was significantly increased in HF patients compared to controls
(total fat: 107mL/m2 vs. 77mL/m2 and ventricular fat: 80mL/m2
vs. 53mL/m2; all P <0.001) (Table 2). In a multivariable regression
model including age, sex, BMI, diabetes mellitus and atrial fibrilla-
tion, HF remained an independent correlate with total epicardial
fat (P =0.003). Interestingly, epicardial fat volume around the atria
was not different between HF patients and controls (P =0.2).
Left ventricular end-systolic volume was higher in HF patients
compared to controls (43mL/m2 vs. 35mL/m2, P = 0.02), whereas
LVEF was lower in HF patients compared to controls (54% vs.
60%, P = 0.002). No differences were found in right ventricular
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 70±10.7 66± 5.5 0.1
Male sex, n (%) 40 (63) 13 (65) 0.9
Body weight (kg) 87.0± 20.3 84.1±13.3 0.5
BSA (m2) 2.0± 0.3 2.0± 0.2 0.9
BMI (kg/m2) 29.6± 5.7 27.2± 4.6 0.08
Systolic BP (mmHg) 139± 22.4 NA
Diastolic BP (mmHg) 72±12.3 NA
Heart rate (b.p.m.) 73.3± 11.9 NA
Co-morbidities, n (%)
Atrial fibrillation 28 (44) 2 (10) 0.006
Hypertension 48 (75) 7 (35) 0.001
CAD 27 (42) 0 (0) <0.0001
T2DM 28 (44) 3 (15) 0.02
NYHA class
II 32 (50) 0
III 32 (50) 0
Medication, n (%)
ACEI 25 (39) 4 (20) 0.1
ARB 22 (34) 4 (20) 0.2
Beta-blockers 58 (91) 6 (30) <0.0001
MRA 24 (38) 0 (0) 0.001
Diuretics 57 (89) 4 (20) <0.0001
Statins 34 (53) 11 (55) 0.9
Echo parameters
Mean septal lateral e’ 7.8± 2.1 9.6± 3.2 0.02
E/e’ 10.1 (8.5–16.6) 8.2 (6.2–12.2) 0.07
E/A ratio 1.1 (0.7–1.5) 0.8 (0.7–1.0) 0.5
Biomarkers
NT-proBNP (ng/L) 885 (451–1517) NA
Troponin T (ng/L) 19 (10–39) NA
CK-MB (U/L) 14 (12–19) NA
CRP (mg/L) 4.4 (1.9–9.7) NA
Leucocytes (109/L) 7.7 (6.0–9.7) NA
HbA1c (mmol/mol) 44 (40–57) NA
eGFR (mL/min/1.73m2) 58.9± 26.1 NA
Quantitative data are presented as mean± standard deviation, or median with
interquartile ranges. Qualitative data are presented as number (%).
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor
blocker; BMI, body mass index; BP, blood pressure; BSA, body surface area; CAD,
coronary artery disease; CK-MB, creatine kinase muscle–brain fraction; CRP,
C-reactive protein; eGFR, estimated glomerular filtration rate; HbA1c, glycated
haemoglobin; HF, heart failure; MRA, mineralocorticoid receptor antagonist; NA,
not available; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New
York Heart Association; T2DM, type 2 diabetes mellitus.
volume and function between groups. Right ventricular contractility
measured by longitudinal strain, however, was lower in HF patients
compared to controls (20% vs. 23%, P = 0.02). Both left and
right atrial volumes were markedly larger in HF patients than
in controls (all differences between HF and controls P < 0.005).
CMR characteristics for HFpEF and HFmrEF are displayed in the




















































































Figure 2 Bar charts comparing total epicardial fat volume
(mL/m2) in different co-morbidities in heart failure. *P < 0.05.
Atrial fibrillation (AF, P = 0.03), type 2 diabetes mellitus (T2DM,
P = 0.001), coronary artery disease (CAD, P = 0.16). Error bars
represent standard error of the mean.
faction were higher in the HFpEF group. Epicardial fat volumes were
comparable between groups.
Associations between epicardial fat
and co-morbidities and plasma
biomarkers
Body mass index and body surface area were not associated with
the extent of epicardial fat volume in HF patients (Table 3). In
contrast, HF patients with type 2 diabetes mellitus and/or atrial
fibrillation had higher epicardial fat volumes than HF patients with-
out these co-morbidities (120mL/m2 vs. 97mL/m2, P = 0.001; and
116mL/m2 vs. 100mL/m2, P = 0.03, respectively) (Figure 2). There
were no significant correlations between patient characteristics
and atrial epicardial fat. For controls, there were no associations
between any of the patient characteristics and total epicardial fat
volume.
Elevated plasma levels of troponin T, CK-MB and HbA1c were
associated with increased total epicardial fat volume (Figure 3).
eGFR showed a negative correlation with total epicardial fat
volume. There were no significant associations between epicardial
fat and NT-proBNP, CRP, or leucocytes in patients with HF.
Associations between epicardial fat
and cardiac function and dimensions
on cardiac magnetic resonance imaging
Left ventricular end-systolic volume was positively associated with
total epicardial fat, whereas LVEF was inversely associated with
total epicardial fat (both R= –0.27, P = 0.03) (Table 3). In addition,
global longitudinal and circumferential strain were negatively corre-
lated with total epicardial fat (R= –0.34, P = 0.006; and R= –0.32,
P = 0.009, respectively). No associations were found between right
ventricular parameters and total epicardial fat volume, except for
right ventricular end-diastolic mass index (R= 0.34, P = 0.005).
Higher left and right atrial volumes were associated with higher
total epicardial fat volume (left and right atrial end-systolic volume
index, both R= 0.28, P = 0.03). Only left atrial end-systolic volume
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Cardiac magnetic resonance imaging characteristics
HF patients (n = 64) Controls (n = 20) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Adipose tissues
Total epicardial fat (mL/m2) 107.0± 27.7 76.9±11.5 <0.0001
Ventricular epicardial fat (mL/m2) 80.1±19.9 52.7±11.1 <0.0001
Atrial epicardial fat (mL/m2) 26.8±12.7 24.2± 6.4 0.2
Volumes and function
LVEF (%) 54.3± 8.5 59.7± 5.4 0.002
LVEDVI (mL/m2) 91.5± 22.3 85.8± 21.5 0.3
LVESVI (mL/m2) 42.7±15.6 35.0±11.6 0.02
LVEDMI (g/m2) 51.7± 17.9 57.6±10.0 0.07
LVCI (L/min/m2) 3.3± 0.6 3.6± 0.8 0.2
RVEF (%) 55.6±11.3 53.3± 6.5 0.3
RVEDVI (mL/m2) 84.0± 20.4 89.7±13.6 0.2
RVESVI (mL/m2) 38.1± 15.2 41.8± 8.2 0.2
RVEDMI (g/m2) 19.0± 5.2 18.3± 2.1 0.4
RVCI (L/min/m2) 3.1± 0.7 3.4± 0.8 0.2
LAESVI (mL/m2) 66.4± 24.1 36.7±14.5 <0.0001
LAEDVI (mL/m2) 45.0± 24.3 18.6±12.4 <0.0001
RAESVI (mL/m2) 51.2± 24.5 36.8±14.2 0.002
RAEDVI (mL/m2) 37.7± 23.9 17.7± 8.1 <0.0001
Strain
LV global longitudinal strain (%) 19.8± 5.1 21.3± 4.4 0.3
LV global circumferential strain (%) 29.4±10.0 30.1± 6.7 0.7
RV global longitudinal strain (%) 19.9± 6.1 23.4± 5.8 0.02
Data are presented as mean± standard deviation.
HF, heart failure; LAEDVI, left atrial end-diastolic volume index; LAESVI, left atrial end-systolic volume index; LV, left ventricular; LVCI, left ventricular cardiac index; LVEDMI,
left ventricular end-diastolic mass index; LVEDVI, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end-systolic volume
index; RAEDVI, right atrial end-diastolic volume index; RAESVI, right atrial end-systolic volume index; RV, right ventricular; RVCI, right ventricular cardiac index; RVEDMI,
right ventricular end-diastolic mass index; RVEDVI, right ventricular end-diastolic volume index; RVEF, right ventricular ejection fraction; RVESVI, right ventricular end-systolic
volume index.
index was associated with atrial epicardial fat volume (R= 0.26,
P = 0.04). In control patients, no CMR parameters were associated
with total epicardial fat volume.
Discussion
In the present study, we found that HF patients with LVEF >40%
had more epicardial fat compared to controls, despite similar
BMI. Also, increased epicardial fat volume was more common in
patients with type 2 diabetes mellitus and to a lesser extent also in
patients with atrial fibrillation. Lastly, epicardial fat was associated
with biomarkers of myocardial damage, glucose metabolism, and
renal dysfunction. To our knowledge, this is the first study that
comprehensively quantified the amount and location (total vs.
ventricular vs. atrial) of epicardial fat in HF with LVEF >40%.
In contrast to previous studies, epicardial fat was not associated
with BMI.6 BMI is an estimate of the overall fat status, but does not
capture information about body fat distribution. It is plausible that
this is the explanation why we did not find differences in BMI, but
only in epicardial fat.
Increased adipose tissue, especially around internal organs,
is indisputably associated with metabolic and haemodynamic



































. hypertrophy and become dysfunctional due to the surplus of
energy.23
When fat cells become dysfunctional, they may start to release
pro-inflammatory adipokines into the bloodstream, possibly lead-
ing to a chronic systemic inflammatory state associated with arte-
rial stiffness, endothelial dysfunction of arterioles, and fibrosis,
which are all implicated in the development of HF with LVEF
>40%.6,22,24,25 One can postulate this same mechanism may hold
true for epicardial fat. This way, it is suggested epicardial fat may
affect the myocardium by directly releasing adipokines near the
cardiomyocytes or via the vasa vasora where adipokines may inter-
act with the myocardium downstream causing cardiac endothelial
dysfunction and remodelling, possibly leading to HF with LVEF
>40% and/or atrial fibrillation.26,27 For HFrEF, epicardial fat may
yield different effects on the myocardium, as in these patients
the pathophysiological mechanism resulting in HF differs from
those with HF with LVEF >40% and epicardial fat seems to be
reduced compared to controls instead of increased.11,28 On the
other hand, epicardial fat may also negatively impact cardiac perfor-
mance by a direct mechanical effect caused by increased pericardial
restraint and enhanced ventricular interdependence, as recently
shown in a haemodynamic exercise study in patients with HFpEF.6
Unfortunately for the present study, dynamic exercise CMR was
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
6 G. van Woerden et al.
Table 3 Associations between epicardial fat, patient characteristics and cardiac magnetic resonance parameters
HF patients (n = 64) Controls (n = 20)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total epicardial fat Ventricular epicardial fat Atrial epicardial fat Total epicardial fat
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
R P-value* R P-value** R P-value† R P-value‡
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age 0.023 0.9 0.01 0.9 0.03 0.8 0.13 0.6
Body weight 0.04 0.7 0.001 0.99 0.09 0.5 0.02 0.9
BSA 0.02 0.9 –0.009 0.9 0.06 0.6 –0.06 0.8
BMI 0.15 0.3 0.09 0.5 0.17 0.2 0.14 0.6
Systolic BP –0.15 0.3 –0.05 0.7 –0.25 0.05 NA NA
Diastolic BP 0.14 0.3 0.07 0.6 0.18 0.2 NA NA
Heart rate 0.09 0.5 0.04 0.8 0.13 0.3 NA NA
Echo parameters
Mean septal lateral e’ –0.04 0.8 –0.01 0.9 –0.07 0.6 –0.32 0.3
E/e’ 0.27 0.07 0.171 0.3 0.17 0.3 –0.45 0.2
E/A ratio 0.40 0.007 0.33 0.03 0.11 0.5 0.59 0.2
Biomarkers
NT-proBNP 0.20 0.1 0.15 0.3 0.2 0.1 NA NA
Troponin T 0.35 0.01 0.32 0.02 0.29 0.04 NA NA
CK-MB 0.37 0.006 0.28 0.04 0.38 0.005 NA NA
CRP 0.09 0.5 0.04 0.7 0.13 0.3 NA NA
Leucocytes 0.03 0.8 0.01 0.9 0.05 0.7 NA NA
HbA1c 0.42 0.002 0.37 0.006 0.36 0.008 NA NA
eGFR 0.43 <0.001 –0.4 0.001 –0.3 0.02 NA NA
CMR parameters
LVEF –0.27 0.03 –0.31 0.02 –0.09 0.5 0.02 0.9
LVEDVI 0.22 0.08 0.32 0.01 –0.02 0.9 0.22 0.4
LVESVI 0.28 0.03 0.37 0.002 0.03 0.8 0.18 0.4
LVEDMI 0.09 0.4 0.17 0.2 –0.05 0.7 0.32 0.2
LVCI 0.25 0.04 0.23 0.02 0.20 0.1 0.06 0.8
RVEF –0.17 0.2 –0.14 0.3 –0.16 0.2 0.23 0.3
RVEDVI 0.12 0.4 0.16 0.2 –0.006 1.0 –0.13 0.6
RVESVI 0.16 0.2 0.17 0.2 0.1 0.5 –0.29 0.2
RVEDMI 0.34 0.005 0.39 0.002 0.15 0.3 0.23 0.4
RVCI 0.15 0.2 0.15 0.2 0.09 0.5 –0.08 0.7
RAESVI 0.28 0.03 0.7 0.03 0.18 0.2 –0.2 0.8
RAEDVI 0.28 0.03 0.28 0.04 0.16 0.2 –0.06 0.8
LAESVI 0.28 0.03 0.28 0.09 0.26 0.04 0.06 0.4
LAEDVI 0.27 0.03 0.26 0.04 0.17 0.2 0.07 0.8
LV global longitudinal strain –0.34 0.006 –0.35 0.005 –0.19 0.1 –0.16 0.5
LV global circumferential strain –0.32 0.009 –0.33 0.008 –0.19 0.1 –0.08 0.7
RV global longitudinal strain –0.23 0.07 –0.14 0.3 –0.27 0.03 –0.28 0.2
BMI, body mass index; BP, blood pressure; BSA, body surface area; CK-MB, creatine kinase muscle–brain fraction; CMR, cardiac magnetic resonance; CRP, C-reactive protein;
eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HF, heart failure; LAEDVI, left atrial end-diastolic volume index; LAESVI, left atrial end-systolic volume
index; LV, left ventricular; LVCI, left ventricular cardiac index; LVEDMI, left ventricular end-diastolic mass index; LVEDVI, left ventricular end-diastolic volume index; LVEF, left
ventricular ejection fraction; LVESVI, left ventricular end-systolic volume index; NA, not available; NT-proBNP, N-terminal pro-brain natriuretic peptide; RAEDVI, right atrial
end-diastolic volume index; RAESVI, right atrial end-systolic volume index; RV, right ventricular; RVCI, right ventricular cardiac index; RVEDMI, right ventricular end-diastolic
mass index; RVEDVI, right ventricular end-diastolic volume index; RVEF, right ventricular ejection fraction; RVESVI, right ventricular end-systolic volume index.
*P-value comparing total epicardial fat volume with patient characteristics and CMR parameters in HF.
**P-value comparing ventricular epicardial fat volume with patient characteristics and CMR parameters in HF.
†P-value comparing atrial epicardial fat volume with patient characteristics and CMR parameters in HF.
‡P-value comparing total epicardial fat volume with patient characteristics and CMR parameters in controls.
not available to measure pericardial restraint and ventricular inter-
dependence. Furthermore, a recent study demonstrated a close
relation between adipose tissue and left atrial electromechanical





. first study demonstrating an association between epicardial fat and
the presence of atrial fibrillation in patients with HFpEF. Atrial
fibrillation may often predispose symptomatic HFpEF.30 How-
ever, any causal relation between epicardial fat, the development
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Regression plots between total epicardial adipose tissue volumes and Ln CK-MB (A), Ln troponin T (B), Ln HbA1c (C), and eGFR
(D). CK-MB, creatine kinase muscle–brain fraction; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin.
of atrial fibrillation and onset or progression of HFpEF needs
further study.
Type 2 diabetes mellitus has previously been associated with vis-
ceral fat around the organs and our finding that epicardial fat is
increased in patients with type 2 diabetes mellitus supports this
relation.31 Additionally, the increased HbA1c and decreased eGFR
levels associated with increased epicardial fat in our cohort are in
line with this relation. Co-morbidities such as atrial fibrillation and
type 2 diabetes mellitus are common in HF and are thought to influ-
ence HF through microvascular inflammation.4,6,32 We observed an
association between epicardial fat, HF with LVEF >40%, atrial fibril-
lation and type 2 diabetes mellitus. It is however unclear whether
epicardial fat is a cause or a consequence of these diseases, or
even merely an innocent bystander. Further studies are needed to
unravel these relationships.
In our cohort, epicardial fat was negatively associated with left
ventricular strain measurements. Whether epicardial fat has a
direct effect on left ventricular systolic contractility is still unclear
and needs to be studied more thoroughly.
Our findings support the idea that epicardial fat may induce
inflammation, which is related to HF and the HF-predominant
co-morbidities such as atrial fibrillation and type 2 diabetes mel-
litus. Epicardial fat may therefore be a marker for the inflammatory
state in HF, atrial fibrillation and type 2 diabetes mellitus.
Limitations
The present study has several limitations. First, the presence of
pericardial effusion could not be ruled out entirely when quantify-













































.. were in correspondence with the T1 times for fat, and not water. In
addition, recent echocardiography was checked for pericardial effu-
sion, which was not observed in these HF patients, therefore min-
imising the chance of overestimation of epicardial fat. Second, the
sample size is relatively small, therefore the chance of false-positive
outcomes increases. Also, due to the relatively small sample size we
were not able to investigate extensive multivariable associations
with epicardial fat. Third, due to the cross-sectional, retrospective
nature of the study, we could not explore direct causal relations
between epicardial fat, co-morbidities, biomarkers, and myocardial
function and contractility. Fourth, our hypothesis that epicardial
fat-associated inflammation leads to myocardial stiffness and HF
with LVEF >40% is not supported by a relationship between epicar-
dial fat and CRP or leucocytes, measured via peripheral venepunc-
ture. The effects of epicardial fat may be too small to be picked
up via a peripheral venepuncture, or total sample size is too small
to pick up these signals. Lastly, data on the control group are lim-
ited, so only our primary question could be answered, and not any
additional questions.
Conclusions
Patients with HF with LVEF >40% have increased epicardial
fat volume compared to controls. Epicardial fat is associ-
ated with type 2 diabetes mellitus and atrial fibrillation. In
addition, epicardial fat is associated with biomarkers of myocar-
dial damage, glucose levels, and renal dysfunction. Further
research should focus on the potential cause–effect relation-
ship between epicardial fat, co-morbidities, and myocardial
damage in HF.
© 2018 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Table S1. Patient characteristics based on HFmrEF and HFpEF.
Table S2. Cardiac magnetic resonance characteristics based on
HFmrEF and HFpEF.
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